Compare Eli Lilly And Co (LLY) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs McKesson Corporation — how do they compare? Eli Lilly And Co trades at $1,223.99 (market cap $1.08T), while McKesson Corporation trades at $893.31 (market cap $105.14B). The key difference: Eli Lilly And Co is far larger — about 10.3× McKesson Corporation's market cap, and Eli Lilly And Co pays the higher dividend (0.57%). Which is the better fit depends on your goals.
| LLY | MCK | |
|---|---|---|
Market Cap | $1.08T | $105.14B |
Sector | Health | Health |
52-Week High | $1.24K | $995.69 |
52-Week Low | $639.43 | $659.01 |
Enterprise Value | $1.13T | $111.67B |
Dividend Yield | 0.57% | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
McKesson (MCK) trades at $879.87, up 1.18% today, with strong momentum from recent earnings beats and raised guidance. The stock shows bullish technical signals, supported by robust revenue growth and solid cash flow generation. Recent news highlights strength in specialty drugs and oncology, driving positive sentiment.
Outlook remains favorable with a consensus price target of $990.67, though thin profit margins and high liabilities pose risks. Continued execution on growth initiatives and cost discipline are key for sustained upside, while macroeconomic pressures and competitive dynamics require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
